All studies
RecruitingObservational

How changing HIV treatment affects sleep, mood, quality of life and health in people around or after the menopause and older adults living with HIV

Thanks to effective modern medicines, many people with HIV are living long, healthy lives. However, ageing and the menopause bring natural bodily changes that can affect sleep, mood, and how medicines feel. Standard clinical trials often do not include enough older adults or women, meaning we know less about their day-to-day experiences with common HIV treatments like Biktarvy (B/F/TAF). The PEARL study is an observational study running across UK NHS clinics. It aims to bridge this knowledge gap by following adults aged 60 and over, as well as women aged 40 to 60. Researchers will look at routine health records and ask some participants who are changing treatments to complete short questionnaires about their quality of life. The study will not test experimental drugs or alter your prescribed care. The results will help doctors offer more tailored HIV treatment in the future.

At a glance

Status
Recruiting
Sponsor
University of Sussex
Enrolment target
620
Start
08 Jun 2026
Estimated completion
08 Jan 2027

What is this study about?

People living with HIV are living much longer, and more than half of adults with HIV in the UK are now aged 50 or older. As we get older, our bodies change. Going through the menopause or simply growing older can lead to poor sleep, changes in mood, and a higher chance of noticing medication side effects. While HIV medicines are thoroughly tested, clinical trials have historically included younger men more than older adults or women. Because of this, doctors need a clearer picture of how these medicines affect everyday well-being in the real world.

This study, called the PEARL study, focuses on an HIV treatment called bictegravir/emtricitabine/tenofovir alafenamide (known as B/F/TAF or Biktarvy). Doctors often choose this combination for older adults because it is generally gentle on the bones and kidneys. However, we still need to know much more about how it affects daily quality of life, energy levels, and emotional health over time.

By gathering information from NHS clinics across the UK, researchers hope to see how both older adults and women around the menopause get on with their treatment. This research does not involve trying unapproved drugs. Instead, it listens to people's lived experiences to help clinics give more personal, supportive care to everyone growing older with HIV.

Key takeaways

  • The PEARL study looks at how HIV treatments affect sleep, mood, and quality of life in older adults and menopausal women.
  • It is an observational study, meaning no experimental drugs are tested and your treatment will not be changed for the research.
  • Open to adults aged 60 and over, or women aged 40 to 60, who take B/F/TAF or are switching treatments.
  • Taking part lasts up to 8 months and uses information from your normal NHS clinic visits.
  • Participants who fill out the optional surveys receive a £20 shopping voucher for each completed questionnaire.

Who may be eligible?

You may be able to join this study if you are living with HIV-1 and receive your care at a participating UK NHS clinic. You must either be aged 60 or older (of any gender), or be an individual who was assigned female at birth and is currently aged between 40 and 60.

In addition, you need to fit into one of two treatment groups. The first group is for people who are currently taking B/F/TAF (Biktarvy) or have taken it in the past. The second group is for people who are about to switch from their current HIV medication to a new one, which can be B/F/TAF or any other standard HIV treatment.

You will not be able to join if you cannot give informed consent to share your medical notes, or if your clinic cannot provide the complete health records needed for the research.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am an adult living with HIV-1.
  2. I am either aged 60 or older, OR an individual assigned female at birth aged 40 to 60.
  3. I currently take B/F/TAF (Biktarvy), have taken it before, or am planning to switch HIV treatments.
  4. I receive my HIV care at a participating UK NHS hospital clinic.
  5. I am happy for researchers to look at routine information from my medical records.
Answer every question to see your result.

What does participation involve?

Taking part in the PEARL study lasts up to 8 months and fits around your usual NHS care. Because this is an observational study, you will not be asked to take experimental drugs, and doctors will not change your medication for the sake of the research.

If you take part, clinic staff will collect routine details from your medical records at the start, after 1 to 2 months, and after 6 to 8 months. This includes routine blood test results, weight, and general health details.

If you are joining the group that is switching treatments, you will also be asked to fill in a short questionnaire about your sleep, mood, and daily life. You will do this three times: at the start, at 1 to 2 months, and at 6 to 8 months. Each survey takes around 30 minutes, and you can fill it in at the clinic or online at home. You will receive a £20 shopping voucher each time you complete a survey to thank you for your time.

Potential risks and benefits

There are no physical health risks from taking part, as the study does not test any new or unproven medicines and will not alter your medical care. The main drawback is that answering the questionnaires takes some time and effort. While taking part will not change your personal treatment, your feedback can directly help doctors improve HIV care and support for older adults and women in the future. Joining is entirely your choice, and you are free to leave the study at any point without it affecting your NHS care.

Locations (7)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • University Hospitals Sussex NHS Foundation Trust
    City only
    Worthing, England
  • University Hospitals Birmingham NHS Foundation Trust
    City only
    Birmingham, England
  • Guy's and St Thomas' NHS Foundation Trust
    City only
    London, England
  • Cardiff & Vale University Lhb
    City only
    Cardiff, Wales
  • Royal Free London NHS Foundation Trust
    City only
    London, England
  • Central and North West London NHS Foundation Trust
    Unverified
    London, England
  • East of England Community Health and Care NHS Trust
    Unverified
    Norwich, England

Common questions

Will taking part change my current HIV medication?

No. The study is purely observational. Any decisions about starting or switching your medicines are made entirely between you and your regular clinic doctor.

Do I need to attend extra hospital appointments?

No. Researchers will collect information during your normal clinic visits. If you are asked to fill out questionnaires, you can do them from home on a computer or smartphone.

How long will I be involved in the study?

Your involvement will last no more than 8 months from the day you agree to take part.

Will I be paid for taking part?

If you are in the group switching treatments and completing questionnaires, you will receive a £20 shopping voucher each time you complete one of the three surveys.

Who is running and paying for this study?

The study is run by researchers at the University of Sussex and is funded by Gilead Sciences, the company that manufactures the HIV medicine B/F/TAF (Biktarvy).

How to find out more

Kate Alford

Always speak to your GP or specialist before deciding to take part in a study.

Interested in taking part?

Register your interest

Share your details and the research team for "How changing HIV treatment affects sleep, mood, quality of l…" will contact you if you may be eligible. Always speak to your GP before agreeing to take part.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.